• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤复发和耐药中的上皮-间质转化、循环肿瘤细胞和癌症干细胞

EMT, CTCs and CSCs in tumor relapse and drug-resistance.

作者信息

Mitra Abhisek, Mishra Lopa, Li Shulin

机构信息

Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Oncotarget. 2015 May 10;6(13):10697-711. doi: 10.18632/oncotarget.4037.

DOI:10.18632/oncotarget.4037
PMID:25986923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4484413/
Abstract

Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy. Although highly efficacious drugs suppressing several subpopulations of CSCs in various tissue-specific cancers are available, recurrence is still common in patients. To find more suitable therapy for relapse, the mechanisms underlying metastasis and drug-resistance associated with relapse-initiating CSCs need to be identified. Recent studies in circulating tumor cells (CTCs) of some cancer patients manifest phenotypes of both CSCs and epithelial-mesenchymal transition (EMT). These patients are unresponsive to standard chemotherapies and have low progression free survival, suggesting that EMT-positive CTCs are related to co-occur with or transform into relapse-initiating CSCs. Furthermore, EMT programming in cancer cells enables in the remodeling of extracellular matrix to break the dormancy of relapse-initiating CSCs. In this review, we extensively discuss the association of the EMT program with CTCs and CSCs to characterize a subpopulation of patients prone to relapses. Identifying the mechanisms by which EMT-transformed CTCs and CSCs initiate relapse could facilitate the development of new or enhanced personalized therapeutic regimens.

摘要

肿瘤复发和转移是晚期癌症患者生存率低的主要原因,尽管进行了成功的切除或化疗。复发和转移的一个主要原因是癌症干细胞(CSCs)的持续存在,它们对化疗具有高度抗性。虽然有高效药物可抑制各种组织特异性癌症中CSCs的几个亚群,但患者复发仍然很常见。为了找到更适合复发的治疗方法,需要确定与复发起始CSCs相关的转移和耐药的潜在机制。最近对一些癌症患者循环肿瘤细胞(CTCs)的研究显示了CSCs和上皮-间质转化(EMT)的表型。这些患者对标准化疗无反应,无进展生存期短,这表明EMT阳性CTCs与复发起始CSCs同时出现或转化为复发起始CSCs有关。此外,癌细胞中的EMT编程能够重塑细胞外基质,打破复发起始CSCs的休眠。在这篇综述中,我们广泛讨论了EMT程序与CTCs和CSCs的关联,以表征易复发患者的一个亚群。确定EMT转化的CTCs和CSCs引发复发的机制有助于开发新的或增强的个性化治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/4484413/951498480155/oncotarget-06-10697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/4484413/c3a09304d2a7/oncotarget-06-10697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/4484413/951498480155/oncotarget-06-10697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/4484413/c3a09304d2a7/oncotarget-06-10697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/4484413/951498480155/oncotarget-06-10697-g002.jpg

相似文献

1
EMT, CTCs and CSCs in tumor relapse and drug-resistance.肿瘤复发和耐药中的上皮-间质转化、循环肿瘤细胞和癌症干细胞
Oncotarget. 2015 May 10;6(13):10697-711. doi: 10.18632/oncotarget.4037.
2
Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.具有干性和上皮间质转化特征的循环肿瘤细胞具有耐药性,并可预测转移性乳腺癌的不良预后。
Mol Cancer Ther. 2019 Feb;18(2):437-447. doi: 10.1158/1535-7163.MCT-18-0584. Epub 2018 Nov 6.
3
The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.癌症干细胞在复发性和耐药性肺癌中的作用
Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4.
4
The bad seed: Cancer stem cells in tumor development and resistance.坏种子:肿瘤发展和耐药中的癌症干细胞。
Drug Resist Updat. 2016 Sep;28:1-12. doi: 10.1016/j.drup.2016.06.006. Epub 2016 Jun 25.
5
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.靶向上皮-间质转化(EMT)以克服癌症中的耐药性
Molecules. 2016 Jul 22;21(7):965. doi: 10.3390/molecules21070965.
6
Clinical significance of epithelial-mesenchymal transition and cancer stem cells.上皮-间质转化与癌症干细胞的临床意义。
J BUON. 2016 Mar-Apr;21(2):312-9.
7
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.原发性新辅助全身治疗能否根除微小残留病?治疗前后播散性及循环肿瘤细胞分析。
Breast Cancer Res. 2016 Feb 12;18(1):20. doi: 10.1186/s13058-016-0679-3.
8
Isolation, identification, and characterization of cancer stem cells: A review.癌症干细胞的分离、鉴定及特性分析:综述
J Cell Physiol. 2017 Aug;232(8):2008-2018. doi: 10.1002/jcp.25759. Epub 2017 Feb 28.
9
Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme.循环肿瘤细胞及其促进癌症转移和复发的进展,重点关注多形性胶质母细胞瘤。
Exp Mol Pathol. 2018 Oct;105(2):166-174. doi: 10.1016/j.yexmp.2018.07.007. Epub 2018 Jul 18.
10
Intersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance.交叠通路:杂交 E/M 细胞和循环肿瘤细胞在癌症转移和耐药中的作用。
Drug Resist Updat. 2024 Sep;76:101119. doi: 10.1016/j.drup.2024.101119. Epub 2024 Jul 14.

引用本文的文献

1
Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy.阴阳1(YY1)作为耐药途径的核心节点:癌症治疗联合策略的潜力
Biomolecules. 2025 Jul 24;15(8):1069. doi: 10.3390/biom15081069.
2
Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression.Tfcp2l1作为缺氧、去分化和肿瘤进展的核心整合因子。
J Exp Clin Cancer Res. 2025 Aug 14;44(1):236. doi: 10.1186/s13046-025-03501-9.
3
Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment.

本文引用的文献

1
Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells.顺铂选择的耐药性通过激活非典型畸胎瘤/横纹肌样瘤细胞中的STAT3/Snail轴与运动性增加和干细胞样特性相关。
Oncotarget. 2015 Jan 30;6(3):1750-68. doi: 10.18632/oncotarget.2737.
2
Integrating autophagy and metabolism in cancer.癌症中自噬与代谢的整合
Arch Pharm Res. 2015 Mar;38(3):358-71. doi: 10.1007/s12272-015-0562-2. Epub 2015 Jan 24.
3
Overcoming EMT-driven therapeutic resistance by BH3 mimetics.
免疫刺激溶瘤腺病毒介导的肿瘤微环境重塑增强免疫检查点抑制剂对免疫原性差的实体瘤的效力
Mol Med. 2025 May 7;31(1):175. doi: 10.1186/s10020-025-01223-4.
4
Intercellular contractile force attenuates chemosensitivity through Notch-MVP-mediated nuclear drug export.细胞间收缩力通过Notch-MVP介导的核药物外排减弱化学敏感性。
Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2417626122. doi: 10.1073/pnas.2417626122. Epub 2025 May 7.
5
hsa-miR-5688 inhibits FOXC1-OCT4/SOX2 feedforward loop that drives chemoresistance in breast cancer stem cells.人源微小RNA-5688抑制FOXC1-OCT4/SOX2前馈环,该前馈环驱动乳腺癌干细胞的化疗耐药性。
Mol Ther Oncol. 2025 Apr 8;33(2):200982. doi: 10.1016/j.omton.2025.200982. eCollection 2025 Jun 18.
6
Neuropilin-1: A Multifaceted Target for Cancer Therapy.神经纤毛蛋白-1:癌症治疗的多面靶点
Curr Oncol. 2025 Mar 31;32(4):203. doi: 10.3390/curroncol32040203.
7
Circulating tumor cell markers for early detection and drug resistance assessment through liquid biopsy.通过液体活检用于早期检测和耐药性评估的循环肿瘤细胞标志物。
Front Oncol. 2025 Apr 7;15:1494723. doi: 10.3389/fonc.2025.1494723. eCollection 2025.
8
Exploring the role of EMT in ovarian cancer progression using a multiscale mathematical model.使用多尺度数学模型探索上皮-间质转化在卵巢癌进展中的作用。
NPJ Syst Biol Appl. 2025 Apr 17;11(1):36. doi: 10.1038/s41540-025-00508-y.
9
Human papillomavirus, vaginal microbiota and metagenomics: the interplay between development and progression of cervical cancer.人乳头瘤病毒、阴道微生物群与宏基因组学:宫颈癌发生发展过程中的相互作用
Front Microbiol. 2025 Jan 22;15:1515258. doi: 10.3389/fmicb.2024.1515258. eCollection 2024.
10
Intricate relationship between cancer stemness, metastasis, and drug resistance.癌症干性、转移和耐药性之间的复杂关系。
MedComm (2020). 2024 Sep 21;5(10):e710. doi: 10.1002/mco2.710. eCollection 2024 Oct.
通过BH3模拟物克服上皮-间质转化驱动的治疗耐药性。
Oncoscience. 2014 Nov 5;1(11):706-8. doi: 10.18632/oncoscience.93. eCollection 2014.
4
Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.捕获上皮-间质转化的循环肿瘤细胞以检测肿瘤进展。
Clin Cancer Res. 2015 Feb 15;21(4):899-906. doi: 10.1158/1078-0432.CCR-14-0894. Epub 2014 Dec 16.
5
Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers.细胞表面波形蛋白:一种用于分离表达上皮-间质转化标志物的新型肝干细胞样癌细胞——胞质波形蛋白阳性(csVimentin(+))且CD133阴性(CD133(-))的定位错误蛋白 。
Int J Cancer. 2015 Jul 15;137(2):491-6. doi: 10.1002/ijc.29382. Epub 2014 Dec 18.
6
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.PI3K/mTOR 双重抑制剂 VS-5584 优先针对肿瘤干细胞。
Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28.
7
Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.电离辐射通过生存素维持胶质母细胞瘤细胞去分化为干细胞样表型:可能与放射抗性有关。
Cell Death Dis. 2014 Nov 27;5(11):e1543. doi: 10.1038/cddis.2014.509.
8
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.卵巢癌干细胞表达ROR1,它可成为抗癌干细胞治疗的靶点。
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71. doi: 10.1073/pnas.1419599111. Epub 2014 Nov 19.
9
Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation.对小鼠进行的正向遗传学筛选揭示了转移再激活的介导因子和抑制因子。
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16532-7. doi: 10.1073/pnas.1403234111. Epub 2014 Nov 5.
10
Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.结合基于上皮细胞粘附分子和细胞表面波形蛋白的方法进行循环肿瘤细胞计数以监测乳腺癌治疗反应
Clin Chem. 2015 Jan;61(1):259-66. doi: 10.1373/clinchem.2014.228122. Epub 2014 Oct 21.